Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Risperidone
Drug ID BADD_D01951
Description Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder.[L12885] It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).[L12885] Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively.[L1212,L1213] Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain.[L1213,A1115] Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's binding affinity to D2 receptors,[L1212,L1213,A1115] and carries lesser activity at several off-targets which may responsible for some of its undesirable effects.[L12885]
Indications and Usage Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder.[L12885] It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.[L12885] Risperidone is additionally indicated in Canada for the short-term symptomatic management of aggression or psychotic symptoms in patients with severe dementia of the Alzheimer type unresponsive to nonpharmacological approaches.[L12906] Risperidone is also used off-label for a number of conditions including as an adjunct to antidepressants in treatment-resistant depression.[A177226]
Marketing Status approved; investigational
ATC Code N05AX08
DrugBank ID DB00734
KEGG ID D00426
MeSH ID D018967
PubChem ID 5073
TTD Drug ID D01AZG
NDC Product Code 12578-303; 57451-1185; 64567-0003; 65757-728; 65862-365; 12496-0090; 13668-035; 13668-039; 50458-306; 50458-325; 51759-410; 55700-897; 59746-050; 65841-670; 68071-2706; 68084-277; 69238-2108; 70518-1613; 70518-2969; 70518-3741; 71610-045; 71610-246; 0615-8197; 0615-8265; 0904-6360; 63552-180; 42291-913; 49884-315; 51759-850; 55154-4161; 59746-010; 63304-950; 63629-2283; 68084-271; 68382-154; 69238-2113; 70518-1151; 55111-869; 65267-895; 65757-727; 27241-004; 27241-005; 27241-006; 42291-908; 50458-335; 50458-355; 51759-305; 51759-520; 58118-0077; 59746-040; 63629-2284; 65841-642; 65841-668; 0054-0063; 68084-270; 70518-0364; 70518-3087; 70518-3760; 55154-3361; 55154-5899; 63187-264; 63187-642; 63304-643; 65862-167; 68084-273; 71335-0130; 0615-8196; 0904-6358; 71161-131; 27241-003; 49884-403; 50458-302; 50458-308; 51759-960; 63187-439; 68382-155; 70518-1502; 71205-520; 71335-0626; 0904-6361; 65757-725; 13668-037; 27808-002; 43063-908; 43547-344; 49884-311; 49884-401; 54838-563; 59746-030; 63304-951; 65841-641; 65841-667; 68084-272; 70518-1574; 70518-1771; 71610-259; 0615-8198; 72526-102; 72526-104; 63415-0037; 63552-179; 64220-119; 64552-4011; 42291-911; 43547-343; 49884-402; 50458-300; 50458-315; 50458-395; 51759-630; 53002-1596; 65841-640; 65841-666; 68084-274; 68382-114; 68382-115; 70518-1575; 71610-264; 53104-7555; 65015-619; 65757-726; 65841-122; 12496-0120; 42291-909; 43063-254; 43353-412; 43353-720; 43547-339; 49884-212; 50090-3340; 50458-309; 50458-350; 51759-740; 59746-020; 62135-929; 63304-949; 68382-156; 70518-1568; 70518-1763; 71335-0459; 71335-0740; 0615-8288; 72526-103; 52038-007; 65372-1105; 27241-002; 43547-340; 43547-341; 43547-342; 50090-3344; 50458-305; 50458-307; 50458-596; 63187-418; 65162-673; 65841-669; 69238-2110; 70518-2130; 70518-3104; 0904-6359; 0904-6362; 13668-036; 13668-038; 27241-001; 42291-910; 42291-912; 43353-432; 50090-3341; 50458-320; 50458-330; 63304-644; 65841-665; 68382-112; 68382-113; 68382-116; 68382-117; 69238-2109; 69238-2111; 69238-2112; 70518-0978; 72162-2037; 72526-101; 0904-6357; 40700-0031; 46602-0050; 65267-303; 71161-132; 13668-040
UNII L6UH7ZF8HC
Synonyms Risperidone | Risperdal Consta | Consta, Risperdal | Risperidal | R-64,766 | R 64,766 | R64,766 | R-64766 | R 64766 | R64766
Chemical Information
Molecular Formula C23H27FN4O2
CAS Registry Number 106266-06-2
SMILES CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Amimia17.02.03.0080.000121%Not Available
Behaviour disorder19.01.01.0050.001564%Not Available
Brief resolved unexplained event17.02.05.066; 22.11.02.012; 18.04.15.0060.000121%Not Available
Compulsive lip biting19.06.05.011; 07.05.01.0210.000412%Not Available
Cross sensitivity reaction10.01.01.0360.000303%Not Available
Dilated cardiomyopathy02.04.01.0170.000303%Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.0380.005589%Not Available
Gait inability08.01.02.011; 17.02.05.069--Not Available
Galactocele21.05.02.005; 18.06.02.0050.000121%Not Available
Graves' disease10.04.08.014; 06.09.04.009; 05.02.02.0090.000242%Not Available
Heavy menstrual bleeding21.01.03.005--Not Available
Hepatic cytolysis09.01.07.0360.000849%Not Available
Hyperglycaemic hyperosmolar nonketotic syndrome17.02.04.022; 14.07.04.009; 05.07.04.0090.000546%Not Available
Hypometabolism14.11.01.0190.000182%Not Available
Hyponatraemic coma17.02.09.012; 14.05.04.0120.000121%Not Available
Idiopathic intracranial hypertension17.07.02.0110.000606%Not Available
Immobilisation syndrome15.03.05.017; 08.01.03.0920.000121%Not Available
Intermenstrual bleeding21.01.01.015--Not Available
Intestinal pseudo-obstruction07.02.02.0200.000364%Not Available
Ketosis-prone diabetes mellitus14.06.01.016; 10.04.08.016; 05.06.01.0160.000182%Not Available
Malignant catatonia19.11.01.0030.000242%Not Available
Myocardial injury02.04.02.0460.000303%Not Available
Orbital myositis15.05.01.014; 06.04.11.0050.000182%Not Available
Paroxysmal perceptual alteration19.10.04.0090.000303%Not Available
Physical deconditioning08.01.03.0960.000121%Not Available
Portal vein cavernous transformation24.03.03.050; 09.01.06.0290.000242%Not Available
Potentiating drug interaction08.06.03.0150.000303%Not Available
Propulsive gait17.01.05.015; 08.01.02.0130.000121%Not Available
Pseudogynaecomastia21.05.04.019; 14.03.02.0320.000388%Not Available
Psychotic symptom19.03.01.0120.001394%Not Available
The 36th Page    First    Pre   36 37    Next   Last    Total 37 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene